Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 996 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Comparison control condition Clear all

Conditions: Traumatic Brain Injury (TBI) Patients, Severe Traumatic Brain Injury
Interventions: SeeMe Multimodal Auditory Command Protocol; Diagnostic Test
Lead sponsor: Stony Brook University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 516 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 48
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 42 more

Conditions: Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders
Interventions: Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo, Matching Intramuscular Placebo, My-E-Health SENTINEL Digital Monitoring and Human-Gated Escalation Platform, Standardized Psychological Preparation, Integration and Recovery Support, Garmin-Enabled Longitudinal Wellness Monitoring; Drug · Device · Behavioral + 1 more
Lead sponsor: Clive Michelsen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Basalt, Colorado

Conditions: Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
Interventions: Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy; Device · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greenville, North Carolina

Conditions: Diabetic Peripheral Neuropathy
Interventions: Clinical Evaluation, Evaluation of Passive Ankle Stiffness, Gait Biomechanics, Gait Biofeedback, Plantar Pressure Biofeedback Gait Training, Propulsion Biofeedback Gait Training; Other
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 45 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Cancer, Alcohol Use
Interventions: TRAC: Tracking and Reducing Alcohol Consumption, No intervention; Behavioral · Other
Lead sponsor: Carolyn Lauckner; Other
Eligibility: 18 Years to 39 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Skin Cancer
Interventions: Health Chat including Indoor Tanning, Health Chat excluding Indoor Tanning; Behavioral
Lead sponsor: Klein Buendel, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,607 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2022
U.S. locations: 4
States / cities: Fort Collins, Colorado • Golden, Colorado • Storrs, Connecticut + 1 more

Conditions: Breast Neoplasms
Interventions: Xentuzumab, Placebo, Everolimus, Exemestane; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 16
States / cities: Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more

Conditions: Fecal Incontinence, Neurogenic Bowel
Interventions: Dose Response - NS and USP Glycerin - First Intervention, Effectiveness - NS and USP Glycerin - Second Intervention; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more

Conditions: Aggression, Self-injurious Behavior
Interventions: Trad FCT, Mult FCT, Mult FCT + Stimulus Fading; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 3 Years to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Somerset, New Jersey

Conditions: Social Anxiety, Social Anxiety Disorder
Interventions: Online Interpretation Training Condition 1, Online Interpretation Training Condition 2; Behavioral
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 8 Years to 12 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Psoriatic Arthritis
Interventions: methotrexate (MTX), adalimumab (ADA); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more

Conditions: Alcohol Drinking, Ethanol Intoxication, Breastfeeding
Interventions: Low-alcohol level exposure, Breast-pumping time; Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Breast Cancer, Obesity
Interventions: Group phone counseling, Newsletter; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Up to 75 Years · Female only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Schizophrenia, Psychotic Disorders
Interventions: Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 337 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more

Conditions: Psychosis, Anxiety, Depression, Rumination
Interventions: Smartphone-based Mindfulness Exercise, Smartphone-based Psychoeducation, Neutral Control Message; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Systemic Sclerosis, Scleroderma
Interventions: Anifrolumab (blinded), Placebo (blinded), Anifrolumab (unblinded, open label); Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 26
States / cities: Scottsdale, Arizona • Chula Vista, California • Los Angeles, California + 23 more

Conditions: Smoking, Smoking Behaviors, Smoking Cessation
Interventions: Take a Break plus Nicotine replacement therapy (NRT) Sampling, The Comparison, Community Paramedicine Standard Plus Enhanced Implementation Program, Community Paramedicine Standard Implementation Program; Behavioral · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sexual Arousal Disorder
Interventions: Placebo, SST-6007; Drug
Lead sponsor: Strategic Science & Technologies, LLC; Industry
Eligibility: 21 Years to 60 Years · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Ventricular Dysfunction, Left, Ventricular Function, Left, Echocardiography, Ultrasonography, Point-of-Care Systems, Heart Function Tests, Stroke Volume, Federated Learning, Machine Learning, Artificial Intelligence (AI), Deep Learning, Neural Networks, Computer, Image Interpretation, Computer-Assisted, Diagnosis, Computer-Assisted, Sensitivity and Specificity, ROC Curve
Interventions: Focused Cardiac Point-of-Care Ultrasonography, FL-POCUS Federated Machine-Learning Analysis System; Diagnostic Test · Device
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 1
States / cities: New York, New York

Conditions: Symptomatic Non-erosive Gastroesophageal Reflux Disease
Interventions: Vonoprazan, Placebo; Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Mentor, Ohio

Conditions: Arthritis
Interventions: Arthritis Quick Start, Delayed treatment intervention; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 690 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Systemic Lupus Erythematosus
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 39
States / cities: La Jolla, California • La Mesa, California • San Diego, California + 34 more

Search by objective public record fields.

SeeMe: Using Automated Facial Tracking to Detect Voluntary Behavior in Brain Injury

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder

Providing Optimal PEEP During Mechanical Ventilation for Obese Patients Using Esophageal Balloon

Walking Function in Diabetic Peripheral Neuropathy

Evaluating an mHealth Intervention for Reducing Alcohol Use Among Adolescent and Young Adult Cancer Survivors

Engaging Moms on Teen Indoor Tanning Through Social Media

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Refinements of Functional Communication Training

Interpretive Biases in Children With Social Anxiety

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Alcohol, Breast Cancer, and Metabolism

Rural Women Connecting for Better Health

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

Pilot Study of Sensor-Informed Smartphone-based Mental Health Interventions for Mood in Early Psychosis

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

Take A Break - Rural

Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder

Federated Learning for Point-of-Care Cardiac Ultrasound

A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks

Arthritis Self-Management Education Program

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus